(A) The chemical structure of investigational drug VERU-111. The drug exhibits broad antiviral activity because it disrupts the intracellular transport of viruses, including SARS CoV-2, along microtubules, which is critical for viruses to cause infection. It also promotes strong anti-inflammatory effects. (B) The chemical structures of leflunomide and its active metabolite teriflunomide. Their potential therapeutic values in COVID-19 patients are attributed to antiviral effects by dihydroorotate dehydrogenase inhibition and to anti-inflammatory effects.